Company Overview of Albireo AB
Albireo AB, a biotechnology company, focuses on the development of therapeutic drugs for gastrointestinal diseases. It develops A3309, an oral compound for the treatment of patients with chronic idiopathic constipation. The company also develops A4250, a hepatology candidate for the treatment of primary biliary cirrhosis, progressive familial intrahepatic cholestasis, and alagille syndrome. Albireo AB was founded in 2008 and is based in Gothenburg, Sweden.
Arvid Wallgrens Backe 20
Gothenburg, 413 46
Founded in 2008
Key Executives for Albireo AB
Director of Finance & Operations
Chief Operating Officer and Director
Vice President of Development
Vice President of Pre-Clinical
Compensation as of Fiscal Year 2013.
Albireo AB Key Developments
Albireo AB Presents at BIO-Europe 2012, Nov-12-2012
Nov 9 12
Albireo AB Presents at BIO-Europe 2012, Nov-12-2012 . Venue: CCH Congress Center Hamburg, Am Dammtor / Marseiller Str, 20355 Hamburg, Germany.
Albireo AB Grants Orphan Drug Designation for A4250 from the US FDA
Nov 8 12
Albireo AB announced that A4250 (an inhibitor of the ileal bile acid transporter, IBAT/ASBT) has been granted orphan-drug designation by the U.S Food and Drug Administration (FDA) for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and Primary Biliary Cirrhosis (PBC). A4250 is an inhibitor of the bile acid transport mechanism and will decrease the toxic levels of bile acids in the liver cells.
Albireo AB Receives Opinion for Orphan Drug Designation for A4250 for Severe Liver Diseases
Jul 24 12
Albireo AB announced that the European Medicines Agency Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on an application for orphan medicinal product status for the company's lead hepatology candidate, A4250, for the treatment of: Primary Biliary Cirrhosis (PBC), Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome. The positive opinion of the COMP has now been forwarded to the EU commission for final approval. The designation would allow Albireo ten years of marketing exclusivity in EU member countries after obtaining market authorization, as well as streamlined regulatory review processes and registration. PBC is a slowly progressive autoimmune disease of the liver, primarily affecting women; average age when symptoms start is around 40-50 years of age. It is characterized by destruction of bile ducts resulting in an increased bile acid concentration in the liver inducing inflammation and cirrhosis. There are more than 100.000 patients with PBC in Europe. Main symptoms are fatigue, severe itching and symptoms of cirrhosis. There is no cure for PBC, some therapeutic alternatives may slow disease progression and relieve symptoms but some patients may need liver transplantation. PFIC is a rare disease (estimated prevalence at birth 1/50.000 corresponding to more than 10.000 patients in the European Union) caused by a genetic defect impairing the transport of bile acids thereby inducing toxic levels of bile acid products in the liver inducing severe symptoms such as itching and scarring of the liver (cirrhosis) early in life. Although milder forms exist, most patients will develop symptoms in early childhood. Without any treatment, PFIC will lead to cirrhosis by age 10-20 years. In addition to supportive measures, the most common therapeutic modality is a surgical procedure thereby a portion of the bile production is either diverted to a stoma bag or by intestinal bypass to the large bowel. If the patient does not get better, or if there is evidence of liver cancer, then liver transplantation may be needed. Alagille syndrome is an inherited disease in which the patient has fewer than the normal number of bile ducts to increased concentration of bile acids in the liver which induce damage to the liver cells. The estimated number of patients with Alagille syndrome in the European Union is approximately 10.000-20.000. Jaundice, severe itching and growth problems are caused by the liver failure. Approximately 75% of the children diagnosed with Alagille syndrome live to 20 years of age; deaths most often caused by liver failure or heart complications. A4250 belongs to a class of inhibitors of the ileal bile acid transporter (IBAT, syn. apical sodium-dependent bile acid transporter ASBT). Usually bile excreted into the small bowel is being reused by a transport mechanism in which bile acids are absorbed in the distal part of the small bowel. A4250 decreases this re-absorption and will reduce the toxic levels of bile acids in the diseases described above. By using a specialized delivery technology, the bile acids will be neutralized in the large bowel.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|